Adverse Effects and Treatment Discontinuation of Blood Pressure-Lowering Drugs and Combinations: A Network Meta-Analysis - PubMed
2 hours ago
- #Blood pressure-lowering drugs
- #Treatment discontinuation
- #Adverse effects
- Network meta-analysis of 716 short-term trials with 159,362 participants assessed adverse effects and discontinuation of blood pressure-lowering drugs and combinations.
- Treatment discontinuation due to adverse events was significantly higher with calcium channel blockers (OR 1.43), angiotensin-converting enzyme inhibitors plus CCBs (OR 1.46), and β-blockers plus thiazide diuretics (OR 1.58) compared to placebo.
- ARB-containing regimens, especially ARB monotherapy (OR 0.73) and ARBs plus CCBs (OR 0.61), had significantly fewer treatment discontinuations than placebo, suggesting better tolerability and symptomatic improvement.
- Combination therapies generally showed higher tolerability than monotherapies in terms of discontinuation due to adverse events, with some regimens outperforming placebo.
- All regimens significantly increased dizziness, and all except CCBs significantly decreased headache compared to placebo, highlighting varied side effect profiles.
- The findings, based on trial-level data and network meta-analysis assumptions, emphasize class- and regimen-specific tolerability but may not directly apply to individual patients.